News and Announcements
Elixinol products launch in New Zealand following change in legislation
- Published January 23, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Elixinol products are now available to patients in New Zealand.
- The launch of products in new Zealand comes following the change in legislation which removes CBD as a Class B1 controlled drug.
- Patients may now import up to three months supply of CBD with prescriptions.
Elixinol Global Limited (ASX:EXL) is pleased to announce that Elixinol branded cannabidiol (CBD) products are now available on a prescription basis in New Zealand.
The launch of products in new Zealand comes following tthe passage of New Zealand’s Misuse of Drugs (Medicinal Cannabis) Amendment Act in December 2018, which classifies CBD with low levels of THC as prescription medicine and removes CBD as a Class B1 controlled drug.
The Act now recognises CBD as a substance with ‘therapeutic value with little or no psychoactive properties’.
Patients can now import up to three months worth of CBD products with a prescription.
Elixinol’s capsules, topicals and tinctures including liposomes meet the required standard for import into New Zealand.
Paul Benhaim, CEO of parent company EXL, said: ” Now, this change in New Zealand enables Elixinol to ship CBD to patients who have been requesting it for years.
We are delighted to be one of the first companies to supply New Zealand patients with the range our US customers have been benefiting from for years”.
About Elixinol Global Limited (ASX: EXL)
Elixinol Global Limited (ASX: EXL; OTCQX: ELLXF) through its businesses has a global presence in the cannabis industry including hemp-derived CBD dietary supplements, hemp food and wellness products, as well as cultivation and manufacture of medicinal cannabis products.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
